Eli Lilly Announces Phase 3b Clinical Results for Taltz and Zepbound Combination Therapy
LLY Lilly(Eli) & Co
$1179.27 +0.83%
View chart & analysis → - 1Eli Lilly reported that the combination therapy of Taltz and Zepbound changed more immune and metabolic biomarkers in adults with moderate-to-severe plaque psoriasis and obesity or overweight than Taltz monotherapy.
- 2At week 36, the dual therapy identified 482 changed proteins among proteins and 467 changed genes among genes.
- 3Mark Genovese, Senior Vice President of Immunology Development, said these results support a more comprehensive psoriasis care approach that also manages obesity.
So what's the key point?
Eli Lilly announced results showing that using two medicines together is effective. This supports a broader treatment method that manages both psoriasis and obesity at the same time.
Source Clinical Trials Arena +3 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.